课题基金 / 基金详情

Development of novel antitumor immunogenetherapy using artificial cancer antigen-secreting tumors.

Development of novel antitumor immunogenetherapy using artificial cancer antigen-secreting tumors.
使用人造癌症抗原分泌肿瘤开发新型抗肿瘤免疫基因疗法。
批准号:
15590353
负责人:
TAMURA Yasuaki
金额:
$2.11万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2003
资助国家:
日本
项目状态:
已结题
起止时间:
2003 至 2004

项目摘要

项目成果

TAMURA Yasuaki的其他基金

相似基金

相关文献

中文摘要
翻译
通过该科学研究资助金,我们检测了Survivin-Fc嵌合体蛋白的分泌形式诱导Survivin特异性CTL的能力。我们已经证明凋亡抑制因子Survivin是肿瘤抗原,CD8 + T细胞识别Survivin衍生肽和HLA-A24 MHC I类复合物.首先,我们将编码Survivin的基因与腺E3衍生的信号序列和IgG的Fe部分融合。将该基因转染K562细胞,建立了稳定的双克隆(ssSVN-K562).测定培养上清中Survivin蛋白的分泌量。Survivin蛋白的表达量低于lng/ml.将来自HLA-A24阳性的荷瘤患者的CD8 + T细胞与自体树突状细胞和ssSVN-K562共培养。然而,Survivin特异性CTL不能诱导。我们推断如此低量的分泌型Survivin不能刺激CTL。接下来,我们建立了肿瘤细胞克隆(CT-26和EG.7),其用融合有腺E3衍生的信号序列的Hsp72或Hsc73基因转染。已充分确定Hsp72和Hsc73结合细胞内广泛的肿瘤抗原肽。肿瘤攻击实验显示这些克隆具有免疫原性,一些肿瘤克隆被自发排斥。此外,用这些克隆免疫激发针对亲本肿瘤系的强大CTL应答。此外,用经照射的分泌Hsp的肿瘤治疗已建立的肿瘤揭示了肿瘤的生长迟缓,并显示出存活益处(手稿在提交中)。我们还证明了Hsp 72和Hsc 73的分泌形式结合抗原肽,例如Ova衍生肽。这些结果提示,用分泌型Hsp72或Hsc73基因转染肿瘤细胞可能是一种很有前途的免疫基因治疗方法。
英文摘要
By this Grant-in-Aid for Scientific Research, we have examined the ability of secretary form of Survivin-Fc chimera protein for induction of Survivin- specific CTL.1. We have demonstrated that Survivin, inhibitor of apoptosis, is the tumor antigen and CD8+ T cells recognize the Survivin- derived peptide and HLA-A24 MHC class I complex.2. First, we have made the gene encoding Survivin fused with adeno E3-derived signal sequence and Fe portion of IgG. K562 cells were transfected with this gene and established couple of stable clones (ssSVN-K562).3. Quantity of secreted Survivin protein in the culture supernatant was measured. Less thanlong/ml of Survivin protein was detected.4. CD8+ T cells from HLA-A24-positive, tumor-bearing patients were cocultured with autologous dendritic cells and ssSVN-K562. However, Survivin-specific CTLs were unable to induce. We reasoned that such a low amount of secreted Survivin could not stimulate CTLs.5. Next, we have established the tumor cell clones (CT-26 and EG.7), which were transfected with Hsp72 or Hsc73 gene fused with adeno E3-derived signal sequence. It is well established that Hsp72 and Hsc73 bind broad array of tumor antigen peptide within the cells. Tumor challenge assay revealed that these clones become immunogenic and some tumor clones were rejected spontaneously. Furthermore, immunization with these clones elicits powerful CTL responses against parental tumor lines. In addition, treatment with irradiated Hsp secreting tumor for established tumors revealed the growth retardation of tumors and showed the survival benefits (manuscript in submitting). We also demonstrated that secretary form of Hsp72 and Hsc 73 binds an antigenic peptide, such as Ova-derived peptide.6. These data suggest that transfection with secretary form of Hsp72 or Hsc73 gene to tumor cells might bea promising immunogenetherapy.
期刊论文(18)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1186/1479-5876-2-19
发表时间: 2004-06-13
期刊: Journal of translational medicine
影响因子: 7.4
作者: [Tsuruma T, Hata F, Torigoe T, Furuhata T, Idenoue S, Kurotaki T, Yamamoto M, Yagihashi A, Ohmura T, Yamaguchi K, Katsuramaki T, Yasoshima T, Sasaki K, Mizushima Y, Minamida H, Kimura H, Akiyama M, Hirohashi Y, Asanuma H, Tamura Y, Shimozawa K, Sato N, Hirata K]
通讯作者: Hirata K
Kojima, T., Tamura, Y., et al.: "Granulocyte-macrophage colony-stimulating factor gene-transduced tumor cells combined with tumor-derived gp96 inhibit tumor growth in mice."Hum.Gene Ther.. 14. 715-728 (2003)
Kojima, T.、Tamura, Y. 等人:“粒细胞-巨噬细胞集落刺激因子基因转导的肿瘤细胞与肿瘤来源的 gp96 结合可抑制小鼠肿瘤生长。”Hum.Gene Ther.. 14. 715-
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
DOI: 10.1158/1078-0432.ccr-03-0817
发表时间: 2005-02-15
期刊: CLINICAL CANCER RESEARCH
影响因子: 11.5
作者: [Idenoue, S, Hirohashi, Y, Sato, N]
通讯作者: Sato, N
Aberrant expression and potency as a cancer immunotherapy target of IAP family, Livin/ML-IAP in Lung Cancer
IAP 家族 Livin/ML-IAP 在肺癌中的异常表达和作为癌症免疫治疗靶标的效力
DOI: --
发表时间: 2005
期刊: Clin. Cancer Res. 11
影响因子: --
作者: [Harlu, H., Hirohashi, Y., Torigoe, T., Tamura, Y., Aketa, K., Kitamura, H., Idenoue, S., Hariu, M., Kamiguchi, K., Mano, Y., Kanaseki, T., Tsukahara, T., Shijubo, N., Sato, N.]
通讯作者: N.
共 9 条
    The development of combined cancer therapy targeting hypoxic microenvironment
    Hypoxia-inducible ERO1-α acts as a member of pre-peptide loading complex and regulates immune responses in the context of MHC class I and class II molecules
    • 批准号:
      21590400
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $3.08万
    • 财政年份:
      2009
    • 负责人:
      TAMURA Yasuaki
    • 依托单位:
    Induction of tumor antigen-specific CTL by Hsp90-antigen fusion DNA vaccine
    • 批准号:
      19590357
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $3.0万
    • 财政年份:
      2007
    • 负责人:
      TAMURA Yasuaki
    • 依托单位:
    Identification of Hsp90-specific receptor expressed on human dendritic cells and its application for cancer immunothearpy
    • 批准号:
      17590309
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.37万
    • 财政年份:
      2005
    • 负责人:
      TAMURA Yasuaki
    • 依托单位:
    海外基金